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Objective: Relevance of cardiac autonomic neuropathy has not been 
fully recognized and there is no standardized treatment protocol. 
Aim: To evaluate the effects of alpha-lipoic acid on the beat-to-beat 
vectorcardiographic parameters, namely spatial QRS-T angle, QT 
dispersion (QTd) and corrected QT interval (QTc) in type 2 diabetes 
mellitus persons with cardiac autonomic neuropathy. Research designs 
and methods: Our study involved 33 persons with definite stage of cardiac 
autonomic neuropathy and diabetes mellitus type 2, which were assigned 
to each of two groups: one took standard antihyperglycaemic treatment 
(n=15, control group) and the other (n=18) in addition to standard therapy 
- 600 mg of alpha-lipoic acid daily for three months. The analysis of 
vectorcardiographic parameters was performed. Results: It was found out 
that alpha-lipoic acid contributed to decrease of the vectorcardiographic 
parameters, namely QRS-T angle, QTd and QTc. Conclusions: The 
positive influences of alpha-lipoic acid suggest the usefulness of its 
prescription to type 2 diabetes mellitus persons with definite stage of 
cardiac autonomic neuropathy. The efficacy of alpha-lipoic acid is the result 






Type 2 diabetes mellitus 
1. Introduction
Diabetes mellitus (DM) is a non-infectious illness with 
worldwide increasing prevalence. DM and state of chro-
nic insulin resistance are associated with the development 
and progression of nervous and cardiovascular diseas-
es. The pivotal role of chronic diabetic complications 
deve-lopment plays oxidative stress (OS), which is caused 
by an imbalance between accumulation and production of 
reactive oxygen species (ROS). Development of chronic 
hyperglycaemia is associated with endothelial nitric oxide 
synthase activity impairment and increasement of ROS 
production, thus resulting in diminished bioavailability of 
nitric oxide and increased OS [1-3].
Development of cardiac autonomic neuropathy (CAN) 
among patients with DM often causes heart rate control 
abnormalities and defects in vascular dynamics. Persons 
with decreased parasympathetic activity have a higher 
resting state heart rates due to development of vagal neu-
ropathy that results in unopposed increased sympathetic 
outflow. Subjects with affection of both parasympathe-tic 
and sympathetic parts of autonomic nervous system 
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have slower heart rates. By development of severe nerve 
dysfunction due to decrease in both parts of autonomic 
nervous system, heart rate is fixed [4]. Chronic hyper-
glycaemia can affect the autonomic nervous system and 
accelerate development and progression of autonomic 
dysfunction. Heart rate variability (HRV) is regulating by 
autonomic innervation, so cardiac autonomic dysfunction 
by DM is associated with a decrement of HRV [5,6].
Reversible prolongation of QTc (corrected QT for heart 
rate) in healthy persons can be caused by hyperinsulinae-
mia, and QTc prolongation can be caused by acute hypo-
glycaemia and chronic hyperglycaemia in diabetic as well 
as in healthy persons [7,8].
In DM patients prolonged QTc was found out during 
overnight hypoglycaemia, that was supported as an ar-
rhythmic background for the development “dead in bed” 
syndrome [9].
Recent data from population-based trials could witness 
that the spatial QRS-T angle become an area of special 
scientific interest. The QRS-T angle is an electrocardio-
gram-derived measure of the difference in mean repolar-
ization and depolarization vectors, can be defined as the 
angle between the mean QRS and T vectors. Widened 
QRS-T angle suggests about the abnormal arrangement 
of ventricular repolarization and has been defined as an 
independent and strong risk indicator for cardiac mortality 
and morbidity compared to electrocardiographic (ECG) 
risk indicators such as QT interval and other traditional 
cardiovascular risk factors [10,11]. The spatial QRS-T angle 
has been recently considered as an independent and strong 
predictor of sudden cardiac death and other morbid and 
mortal cardiac outcomes for various patient groups such 
as elderly subjects [13] and persons with chronic diseases, 
namely type 2 diabetes mellitus (T2DM) [10,11], heart fail-
ure and coronary artery disease (CAD)[12].
Given the role of OS in CAN progression, antioxidants 
demonstrated its effectiveness in prevention or delay of 
CAN diagnosis such as acetyl-L-carnitine, taurine and 
alpha-lipoic acid (ALA) the only water and fat soluble an-
tioxidant [14-19].
Thus, we aimed to evaluate the effects of alpha-lipoic 
acid on the beat-to-beat vectorcardiographic parameters, 
namely spatial QRS-T angle, QT dispersion (QTd), QTc 
in persons with T2DM and definite stage of CAN.
2. Research Design and Methods
2.1 Patients
Our research was aimed to discover the effectiveness 
and safety of ALA on the vectorcardiographic parameters. 
33 T2DM persons with definite stage of CAN were in-
volved to the research. The median glycated hemoglobin 
A1c (HbA1c) of involved patients was 7.1%±0.4%, they 
were aged between 50-59 years and duration of diabetes 
mellitus was 1-6 years.
Patients were examined and treated by endocrinologist 
in the Department of Endocrinology of the Danylo Ha-
lytsky Lviv National Medical University, located on Lviv 
Regional State Clinical Treatment and Diagnostical Endo-
crinological Center.
The study was ethically approved by the Ethics Com-
mittee of the Danylo Halytsky Lviv National Medical 
University, protocol №2 from 18 February 2013 and was 
done according to the principles of the Helsinki Declara-
tion (2004). All persons were orally informed about the 
study and provided a written consent prior to their enroll-
ment in the research. 
The clinical characteristics of the enrolled T2DM pa-
tients with definite stage of CAN are presented in Table 1.
Table 1. Clinical characteristics of patients involved to 
this research
Parameter
T2DM patients with definite stage of 
CAN (n=33)
Control (n=15) Alpha-lipoic acid (n=18)
Group 1 Group 2
Age (years) 55.33±0.95 54.83±0.87
Male gender (%) 53.3%/8 55.6%/10
Female gender (%) 46.7%/7 44.4%/8
Diabetes duration (yrs) 3.6±0.42 3.5±0.42
BMI (kg/m2) 28.89±0.16 28.18±0.33
Medications
ACE inhibitors (%) 80%/12 77.8%/14
β-blockers (%) 20%/3 11.11%/2
Metformin (%) 73.3%/11 55.6%/10
Sulfonylurea (%) 6.7%/1 5.5%/1
Combined hypoglycaemic therapy 
(%) 20%/3 38.9%/7
Hypertension (%) 80%/12 83.3%/15
Note: 
ACE, angiotensin-converting enzyme; BMI, body mass index; CAN, car-
diac autonomic neuropathy; T2DM, type 2 diabetes mellitus.
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2.2 Methods
The duration of the study was 2 years (2015–2017 
yrs). Each patient included to the study was on the sta-
ble hypoglycaemic and antihypertensive treatment for 6 
months and did not take ALA. The diagnosis of CAN was 
performed using the previously proposed diagnostical 
criteria [20]. After confirmation of definite CAN, patients 
were assigned to each of two groups: one took standard 
antihyperglycaemic treatment (n=15, control group) and 
the other (n=18) in addition to standard therapy - 600 mg 
of alpha-lipoic acid daily for three months. 
Highly sensitive method of ion exchange liquid chro-
matography with D-10 analyzer and BIO-RAD reagents 
(United States) was used to measure HbA1c level and 
glucose oxidase method was used to determine the con-
centration of glucose in the blood.
All patients included in our study were assessed by 
measurement of resting 12-lead surface ECG with signal 
size of 10 mm/mV and a paper speed of 25 mm/s. QTc 
was calculated by dividing the QT interval by the square 
root of the preceding normal-to-normal (NN) interval 
time series (Bazett’s formula: QTc=QT/√NN) [21]. The 
difference between the maximum and minimum QTc was 
defined as QTd. ECG-derived measure of the difference in 
mean vectors of depolarization and repolarization (QRS-T 
angle). The frontal planar QRS-T angle was calculated as 
the absolute difference between the frontal QRS wave axis 
and T-wave axis. If the difference exceeded 180°, then it 
was calculated by subtracting from 180° [22]. Resting ECG 
was carried out including the analysis of the following 
parameters: heart rhythm, heart rate, conduction intervals 
and Holter-ЕCG with the measurement of 24 hours ECG, 
HRV parameters and circadian indexes [(ЕCG “ЕС-3Н” 
(“Labtech,” Hungary)] analysis was performed [23].
2.3 Statistical Analysis
Statistical analysis was performed using the ANOVA 
(MicroCal Origin v. 8.0) software. Parametric t-test, non-
parametric Wilcoxon t-test were used for comparisons 
between the two patient groups. Values are expressed as 
mean ± standard error of the mean (SEM). A p-value < 0.05 
was considered as statistically significant.
3. Results
Comparing the HbA1c levels between both patient 
groups before and after treatment, we found out that 
HbA1c was not statistically significant changed after 3 
months of the treatment period (P>0.05).
The features of the QTc, QTd and spatial QRS-T angle 
parameters in persons with T2DM and definite stage of 
CAN after treatment with ALA are shown in Table 2.
Table 2. Changes of the QTc, QTd and QRS-T parameters 
in T2DM persons with CAN after 3-months of alpha-lipo-
ic acid therapy (Δ%, Mean ± SEM)
Parameter T2DM persons with definite stage of CAN (n=33)
Groups Baseline After 3 months of treatment
% change 
from baseline
QTc (ms) Control group (n=15) 433.4±6.45 427.8±4.72 -1.1±1.44%
ALA (n=18) 418.3±8.1 396.3±5.51* -4.9±1.39%
QTd (ms) Control group (n=15) 50.3±4.53 46.0±4.98 -5.6±6.97%




(n=15) 78.0±6.44 69.7±4.26 -6.1±5.52%
ALA (n=18) 77.1±3.27 60.8±5.33* -19.9±6.8%
Notes: 
The data are presented as absolute values and as % change from base-
line, (Δ%, Mean ± SEM); *P<0.05, compared to baseline. CAN, cardiac 
autonomic neuropathy; QTc, corrected QT interval; QRS-T angle, spa-
tial QRS-T angle; QTd, QT interval dispersion; T2DM, type 2 diabetes 
mellitus.
Data, presented in Table 2 allows us to conclude that 
prescription of ALA to T2DM persons with T2DM and 
definite CAN is associated with statistically significant 
decrease in QTc [∆=-4.9±1.39% (P<0.05)], QTd [∆=-
18.1±5.2% (P<0.05)] and the QRS-T angle [∆=-19.9±6.8% 
(P<0.05)]. After 3 months of treatment period no statis-
tically significant changes in the parameters QTc [∆=-
1.1±1.44% (P>0.05)], QTd [∆=-5.6±6.97% (P>0.05)] and 
spatial angle QRS-T [∆=-6.1±5.52% (P>0.05)] in the con-
trol group were found.
4. Discussion
The underlying mechanisms of QTc prolongation in-
cludes genetic factors, alterations in cardiac ion currents, 
cardiovascular autonomic imbalance, metabolic changes 
in myocardium, development of left ventricular (LV) hy-
pertrophy, CAD [7]. The day-night modulation of the QT/
relative risk relation-on 24-h ECG recordings was violated 
in persons with CAN and without CAD, in patients with 
LV hypertrophy or dysfunction, with an increased noctur-
nal QT rate dependence and reversed day-night pattern [24]. 
Reversible prolongation of QTc in healthy persons can be 
caused by hyperinsulinaemia, and QTc prolongation can 
be caused by acute hypoglycaemia or chronic hypergly-
caemia in both diabetic and healthy persons [7, 8].
The changes in QTc can be considered as markers of 
DOI: https://doi.org/10.30564/jer.v2i2.2750 
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cardiovascular autonomic dysfunction and as an important 
component in the potential prognostic value of the risk of 
arrhythmias [24]. Preserving the function of the parasympa-
thetic nervous system in patients with T2DM with CAN 
performs a protective function, and the predominance of 
the sympathetic nervous system or the imbalance of LF/
HF [low- (LF) and high-frequency (HF) bands in HRV] is 
harmful to the electrophysiological activity of the myocar-
dium and may lead to changes in QRS-T [10,11].
Results of one recent trial showed that in persons with 
T2DM and CAN the value of spatial QRS-T angle is 
statistically significantly wider [11]. Furthermore, develop-
ment and severity of CAN were independently associa-ted 
with the greater values of the spatial QRS-T angle. HRV 
parameters were significantly and independently associat-
ed with the spatial QRS-T angle, suggesting the presence 
of a pathophysiological ground linking the electrical, 
structural and functional myocardial disturbances in DM. 
Moreover, from the clinical viewpoint, presence of wider 
spatial QRS-T angle in T2DM patients may point out to 
the presence of CAN, which is often underdiagnosed [10].
In our previously investigations we have found out that 
T2DM persons with definite stage of CAN the QRS-T 
[78.3±1.95 (P<0.001)]; QTc [431.4±2.94 ms (P<0.001)] 
and QTd [53.7±1.49 ms (P<0.01)] were prolonged com-
pared to persons without CAN [25]. An association between 
CAN and prolongation of QT interval was showed in 
many researches and it may predispose to sudden death 
in DM. Increased QTd was also proposed as a marker of 
diabetic cardiac neuropathy. Most of the data regarding 
QT interval and diabetic CAN are in T1DM with only few 
studies in T2DM [7,26].
Among patients with T2DM treated with ALA either 
i.v. or p.o. were observed improvements in glucose dis-
posal. Results of other trials showed decrease in HbA1c, 
lipid peroxidation, antioxidant enzymes and inflammato-
ry markers in patients receiving ALA. ALA has a func-
tion in decreasing damages caused by CAN and inflam-
matory factors as a compound with strong antioxidant 
potential [27-29].
A lot of unique effects of ALA, namely enhancement of 
glucose uptake, antioxidant effects, prevention of beta-cell 
destruction, inhibition of glycation reactions, improve-
ment of neurons function and conduction, restoration of 
vitamins levels has been found in a several clinical and 
experimental study [1,2,6,11,14].
However, further randomized, controlled studies with 
inclusion of large patients’ population and longer duration 
are needed to confirm the efficacy of ALA.
5. Conclusions
In conclusion, the positive influences of alpha-lipoic 
acid on decrease of the QRS-T angle, QTd and QTc are 
partly confirmed by its neurotropic, cardioprotective and 
angioprotective properties; suggests it efficacy in the com-
plex therapy of persons with T2DM and definite stage of 
CAN.
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